Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.
Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.
The European Medicines Agency's committee recommended approval of Eli Lilly's oral weight-loss drug Foundayo for obesity and diabetes, following Novo Nordisk's Wegovy as the second oral obesity drug to win the agency's backing.
Boehringer Ingelheim's investigational dual GIP/GLP-1 agonist survodutide achieved up to 9.8% weight loss in the phase 3 SYNCHRONIZE-2 trial for adults with type 2 diabetes and obesity, meeting primary endpoints but falling short of competing drugs. The results raised tolerability concerns and led to a drop in partner Zealand Pharma's stock.
Novo Nordisk announced it cut 13,000 jobs in the past year and outlined plans to diversify beyond obesity drugs with new pipeline assets and bolt-on acquisitions. CEO Mike Doustdar faced investor skepticism about pricing power and strategy ahead of patent expiries.
Eli Lilly is stepping up legal action against a booming black market for retatrutide, an experimental weight-loss drug the company is counting on to expand its franchise beyond approved medications like Zepbound.